

December 19, 2013

Market Announcement - Exercise of Options

The following is a summary of recent activity in the company's options

	No of	Amount
	Shares	Received
402,500 Options due for expiry in December 2013 exercisable at 20c each,		
(a) Notice of Exercise of Options received:	387,500	\$77,500
(b) Balance of options expired	15,000	0
	402,500	\$77,500
4,000,000 Options due for expiry in December 2014 exercisable at 10c each,		
Notice of Exercise of Options received to date	800,000	\$80,000

The application to list the shares allocated pursuant to the above will be lodged upon completion of the share allotment.

Spiro Sakiris - Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQnovate Limited

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQNovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.